Gephyrin suppresses lung squamous cell carcinoma development by reducing mTOR pathway activation

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians 2019;69(1):7–34.
   Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA. 2016;66(2):115–132.26808342
   PubMedGoogle Scholar
• Jackman DM, Johnson BE. Small-cell lung cancer. Lancet. 2005;366(9494):1385–1396. doi:10.1016/S0140-6736(05)67528-916226617
   PubMed Web of Science ®Google Scholar
• Marinov M, Fischer B, Arcaro A. Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol. 2007;63(2):172–182. doi:10.1016/j.critrevonc.2007.04.00217540577
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441(7092):424–430. doi:10.1038/nature0486916724053
   PubMed Web of Science ®Google Scholar
• Pisick E, Jagadeesh S, Salgia R. Receptor tyrosine kinases and inhibitors in lung cancer. Sci World J. 2004;4:589–604. doi:10.1100/tsw.2004.117
   Google Scholar
• Nawrotzki R, Islinger M, Vogel I, Volkl A, Kirsch J. Expression and subcellular distribution of gephyrin in non-neuronal tissues and cells. Histochem Cell Biol. 2012;137(4):471–482. doi:10.1007/s00418-012-0914-722270318
   PubMed Web of Science ®Google Scholar
• Ogino K, Ramsden SL, Keib N, Schwarz G, Harvey RJ, Hirata H. Duplicated gephyrin genes showing distinct tissue distribution and alternative splicing patterns mediate molybdenum cofactor biosynthesis, glycine receptor clustering, and escape behavior in zebrafish. J Biol Chem. 2011;286(1):806–817. doi:10.1074/jbc.M110.12550020843816
   PubMed Web of Science ®Google Scholar
• Kneussel M, Betz H. Receptors, gephyrin and gephyrin-associated proteins: novel insights into the assembly of inhibitory postsynaptic membrane specializations. J Physiol. 2000;525(Pt 1):1–9.10811719
   PubMed Web of Science ®Google Scholar
• Prior P, Schmitt B, Grenningloh G, et al. Primary structure and alternative splice variants of gephyrin, a putative glycine receptor-tubulin linker protein. Neuron. 1992;8(6):1161–1170. doi:10.1016/0896-6273(92)90136-21319186
   PubMed Web of Science ®Google Scholar
• Schwarz G, Mendel RR, Ribbe MW. Molybdenum cofactors, enzymes and pathways. Nature. 2009;460(7257):839–847. doi:10.1038/nature0830219675644
   PubMed Web of Science ®Google Scholar
• Smolinsky B, Eichler SA, Buchmeier S, Meier JC, Schwarz G. Splice-specific functions of gephyrin in molybdenum cofactor biosynthesis. J Biol Chem. 2008;283(25):17370–17379. doi:10.1074/jbc.M80098520018411266
   PubMed Web of Science ®Google Scholar
• Eguchi M, Eguchi-Ishimae M, Greaves M. The small oligomerization domain of gephyrin converts MLL to an oncogene. Blood. 2004;103(10):3876–3882. doi:10.1182/blood-2003-11-381714751928
   PubMed Web of Science ®Google Scholar
• Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol. 2003;24(1):200–216. doi:10.1128/MCB.24.1.200-216.2004
   Web of Science ®Google Scholar
• Reiss J, Lenz U, Aquaviva-Bourdain C, Joriot-Chekaf S, Mention-Mulliez K, Holder-Espinasse M. A GPHN point mutation leading to molybdenum cofactor deficiency. Clin Genet. 2011;80(6):598–599. doi:10.1111/j.1399-0004.2011.01709.x22040219
   PubMed Web of Science ®Google Scholar
• Stallmeyer B, Schwarz G, Schulze J, et al. The neurotransmitter receptor-anchoring protein gephyrin reconstitutes molybdenum cofactor biosynthesis in bacteria, plants, and mammalian cells. Proc Natl Acad Sci USA. 1999;96(4):1333–1338. doi:10.1073/pnas.96.4.13339990024
   PubMed Web of Science ®Google Scholar
• Pfeiffer F, Graham D, Betz H. Purification by affinity chromatography of the glycine receptor of rat spinal cord. J Biol Chem. 1982;257(16):9389–9393.6286620
   PubMed Web of Science ®Google Scholar
• Kirsch J, Langosch D, Prior P, Littauer UZ, Schmitt B, Betz H. The 93-kDa glycine receptor-associated protein binds to tubulin. J Biol Chem. 1991;266(33):22242–22245.1657993
   PubMed Web of Science ®Google Scholar
• Barnard EA, Skolnick P, Olsen RW, et al. International union of pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev. 1998;50(2):291–313.9647870
   PubMed Web of Science ®Google Scholar
• Durisic N, Godin AG, Wever CM, Heyes CD, Lakadamyali M, Dent JA. Stoichiometry of the human glycine receptor revealed by direct subunit counting. J Neurosci. 2012;32(37):12915–12920. doi:10.1523/JNEUROSCI.2681-12.201222973015
   PubMed Web of Science ®Google Scholar
• Tyagarajan SK, Ghosh H, Yevenes GE, et al. Regulation of GABAergic synapse formation and plasticity by GSK3beta-dependent phosphorylation of gephyrin. Proc Natl Acad Sci U S A. 2011;108(1):379–384. doi:10.1073/pnas.101182410821173228
   PubMed Web of Science ®Google Scholar
• Takahashi H, Katayama K, Sohya K, et al. Selective control of inhibitory synapse development by Slitrk3-PTPdelta trans-synaptic interaction. Nat Neurosci. 2012;15(3):389–398, S381–382.
   Web of Science ®Google Scholar
• Tyagarajan SK, Ghosh H, Yevenes GE, et al. Extracellular signal-regulated kinase and glycogen synthase kinase 3beta regulate gephyrin postsynaptic aggregation and GABAergic synaptic function in a calpain-dependent mechanism. J Biol Chem. 2013;288(14):9634–9647. doi:10.1074/jbc.M112.44261623408424
   PubMed Web of Science ®Google Scholar
• Luscher B, Fuchs T, Kilpatrick CL. GABAA receptor trafficking-mediated plasticity of inhibitory synapses. Neuron. 2011;70(3):385–409. doi:10.1016/j.neuron.2011.03.02421555068
   PubMed Web of Science ®Google Scholar
• Reiss J, Gross-Hardt S, Christensen E, Schmidt P, Mendel RR, Schwarz G. A mutation in the gene for the neurotransmitter receptor-clustering protein gephyrin causes a novel form of molybdenum cofactor deficiency. Am J Hum Genet. 2001;68(1):208–213. doi:10.1086/31694111095995
   PubMed Web of Science ®Google Scholar
• Butler MH, Hayashi A, Ohkoshi N, et al. Autoimmunity to gephyrin in Stiff-Man syndrome. Neuron. 2000;26(2):307–312. doi:10.1016/S0896-6273(00)81165-410839351
   PubMed Web of Science ®Google Scholar
• Rees MI, Harvey K, Ward H, et al. Isoform heterogeneity of the human gephyrin gene (GPHN), binding domains to the glycine receptor, and mutation analysis in hyperekplexia. J Biol Chem. 2003;278(27):24688–24696. doi:10.1074/jbc.M30107020012684523
   PubMed Web of Science ®Google Scholar
• Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991;253(5022):905–909. doi:10.1126/science.17150941715094
   PubMed Web of Science ®Google Scholar
• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471–484. doi:10.1016/j.cell.2006.01.01616469695
   PubMed Web of Science ®Google Scholar
• Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer. 2005;5(12):921–929. doi:10.1038/nrc175316341083
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4(12):988–1004. doi:10.1038/nrd187616341064
   PubMed Web of Science ®Google Scholar
• Zheng N, Shabek N. Ubiquitin ligases: structure, function, and regulation. Annu Rev Biochem. 2017;86:129–157. doi:10.1146/annurev-biochem-060815-01492228375744
   PubMed Web of Science ®Google Scholar